Table 5.
Demographics and clinical characteristics of HAM/TSP patients for biomarker analysis.
| Group R Rapid progressor (n = 15) |
Group S Slow progressor (n = 74) |
Group VS Very slow progressor (n = 7) |
Group C Control∗ (n = 18) |
p-value | Statistical methods | Groups with significant difference | |
|---|---|---|---|---|---|---|---|
| Sex: Female | 12 (80.0%) | 60 (81.1%) | 3 (42.9%) | 14 (77.8%) | 0.1602 | (a) | |
| Age (at present†)∗∗ | 67.0 ± 8.6 | 59.0 ± 10.3 | 59.1 ± 10.5 | 48.3 ± 13.1 | <0.0001 | (b) | R > S, R > C, S > C |
| Age at onset∗∗ | 63.9 ± 9.4 | 44.0 ± 13.7 | 45.0 ± 12.3 | − | <0.0001 | (b) | R > S, R > VS |
| OMDS (range: 0−13)∗∗ | 6.7 ± 1.9 | 5.4 ± 1.8 | 3.0 ± 0.8 | − | <0.0001 | (b) | R > S > VS |
Statistical methods: (a) By Fisher’s exact test, (b) by analysis of variance and Tukey post hoc tests.
∗Normal control group consists of healthy HTLV-1 carrier (n = 10) and non-HTLV-1-infected non-inflammatory neurological disease patients (n = 8), ∗∗Data are expressed as mean ± SD, †Present is defined as the time of the sample collection.
OMDS, Osame Motor Disability Score.